ArticleData in brief2021
Data on sodium tetraborate as a modulation of hypertrophic intracellular signals.
Article in Data in brief, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present work benefits the use of sodium tetraborate to prevent and treat hypertrophic cardiac. The data obtained from the work could serve as a reference point to compare with data obtained in vivo studies with cardiac damage. This research will be an advantage for future researches to stimulate the ones focused on developing food supplements to prevent heart diseases such as cardiac hypertrophic. This article also indicates the data on the optimal concentration of isoproterenol as an inducer of hypertrophy in cardiomyocytes. Also, data of the cytotoxic effect of sodium tetraborate on normal cardiomyocytes is revealed. Finally, data of viability, cell size, proliferation nuclear antigen (PCNA) and apoptosis is shown. The expression of transcription factors linked to hypertrophy such as GATA-4, MEF2c, NFAT, CDk9, and myogenin was also quantified by immunofluorescence. The mRNA expression of adrenergic receptors (alpha and beta), AKT1 and Erk1 / 2 and genes of early response to hypertrophy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.